Key result
Losartan significantly improved flow-mediated dilation compared with atenolol (3.4% vs 2.58%; P=0.01) in patients with type 2 diabetes and hypertension.
Why the study?
Does losartan improve endothelial function and oxidative stress in patients with type 2 diabetes and hypertension compared with atenolol?
Population
13 patients with type 2 diabetes and hypertension
Comparison
Losartan 50 mg twice daily for 4 weeks vs Atenolol 50 mg twice daily for 4 weeks
Design
RCT, randomized, double-blind
Follow-up
4 weeks per treatment period
Authors
Loading...
Supports preferring losartan over atenolol for endothelial protection in T2DM hypertension; extends ARB benefits beyond BP lowering in RCTs.
RCT (n=13)
Double-blind
crossover
Does losartan improve endothelial function and oxidative stress in patients with type 2 diabetes and hypertension compared with atenolol?
Absolute Event Rate: 3.4% vs 2.58%
p-value: p=0.01
Losartan significantly improves endothelial function and reduces oxidative stress compared to atenolol in patients with type 2 diabetes and hypertension, independent of blood pressure lowering.
Flammer et al. (2007) conducted an RCT in type 2 diabetes and hypertension (n=13). losartan vs. atenolol 50 mg twice daily was evaluated on flow-mediated dilation of the brachial artery (p=0.01). Losartan significantly improved flow-mediated dilation compared with atenolol (3.4% vs 2.58%; P=0.01) in patients with type 2 diabetes and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: